Home > Clinical & Pharmacy
Web Content Viewer
Web Content Viewer
Bebtelovimab fights COVID subvariant now dominant in Massachusetts
April 18, 2022

This article is for all providers caring for our members

According to the latest Commonwealth of Massachusetts Department of Public Health guidance, for patients for whom current preferred antiviral treatments (nirmatrevlivr/ritonavir or remdesevir) aren’t appropriate or available, the preferred monoclonal antibody treatment is Bebtelovimab.

Laboratory data has shown Bebtelovimab retains efficacy with a broad range of COVID variants, including Omicron BA.2, which is now dominant in Massachusetts. Bebtelovimab is a newer antibody treatment with emergency use authorization to be given by IV within 7 days of a patient’s first COVID symptoms.

More information